16 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
denoting any gender shall include all genders;
the Schedules and other attachments form part of the operative provision of this Agreement and references
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
14 Oct 22
Regulation FD Disclosure
11:32am
* adjusted for age, gender, insurance type, severity of DR DR patients are generally asymptomatic which contributes to poor adherence and compliance
8-K
EX-99.1
wjym1 d94xyhy
24 Mar 22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update
8:17am
8-K
EX-99.1
wvfu zkhbbn
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
8-K
EX-10.1
uexed
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-2.1
v583bijvkkg
19 Jun 20
Rexahn and Ocuphire Enter into Definitive Merger Agreement
9:02am
425
EX-2.1
h2rw9 j9jvmc7y07rb7n
19 Jun 20
Business combination disclosure
9:00am
8-K
EX-10.1
d161xazwn2sr d90
21 Sep 09
Rexahn Pharmaceuticals and Teva Pharmaceutical Industries Close on a License Agreement
12:00am
8-K
EX-10.1
uvjlzemfwsdrv1w6
30 Jun 09
Rexahn Pharmaceuticals Signs Development and Commercialization Agreement with a Top 20 Pharmaceutical Company for Novel Anti-cancer Compound
12:00am
- Prev
- 1
- Next